Log In
Print
BCIQ
Print
Print this Print this
 

budesonide rectal foam (Uceris)

Also known as: Budenofalk

  Manage Alerts
Collapse Summary General Information
Company Dr. Falk Pharma GmbH
DescriptionFoam formulation of budesonide, a glucocorticosteroid
Molecular Target Corticoid receptors
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsInduction of remission of mild to moderate distal ulcerative colitis (UC); Treat mild to moderate proctitis or proctosigmoiditis; Treat ulcerative colitis (UC)
Regulatory Designation U.S. - Standard Review (Treat ulcerative colitis (UC))
Partner Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$15,624.0M

$14,789.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today